Last reviewed · How we verify

Lendorm — Competitive Intelligence Brief

Lendorm (BROTIZOLAM) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: brotizolam. Area: Neuroscience.

marketed brotizolam Platelet-activating factor receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Lendorm (BROTIZOLAM).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lendorm TARGET BROTIZOLAM marketed brotizolam Platelet-activating factor receptor 1984-01-01
Xanax alprazolam Generic (originally Upjohn/Pfizer) marketed Benzodiazepine (triazolobenzodiazepine) Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4 1981-10-16
Xanax Xanax National Taiwan University Hospital marketed Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (brotizolam class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lendorm — Competitive Intelligence Brief. https://druglandscape.com/ci/brotizolam. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: